Low Concentrations of Resveratrol Potentiate the Antiplatelet Effect of Prostaglandins

Abstract

Resveratrol, a polyphenolic compound found in grapes and other fruits, is thought to contribute to the cardioprotective effect of red wine. While resveratrol exhibits some antiplatelet effect in vitro, the concentrations needed are much higher than those in plasma after consumption of red wine. In the present study, we investigate if resveratrol is able to potentiate the effect of endogenous antiplatelet substances - prostaglandin (PG) I₂ and PGE₁. In human platelet suspension resveratrol at relatively low concentrations (2 or 5 μM), which did not affect platelet function, significantly enhanced the inhibitory activity of PGs on platelet aggregation caused by collagen. The mechanisms underlying this effect may be associated with the inhibition of protein kinase C activation and protein tyrosine phosphorylation, but not with cyclic nucleotide levels and intracellular calcium mobilization in platelets. Our results might provide a possible explanation for the in vivo antiplatelet effect of resveratrol despite the poor bioavailability and the weak in vitro activity.

Resveratrol - prostaglandins - platelet aggregation - protein kinase C - protein tyrosine phosphorylation

References

• 1 Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease.  Lancet. 1992;  339 1523-6.
• 2 Fremont L. Biological effects of resveratrol.  Life Sci. 2000;  66 663-73.
• 3 Olas B, Wachowicz B. Resveratrol, a phenolic antioxidant with effects on blood platelet functions.  Platelets. 2005;  16 251-60.
• 4 Bertelli A A, Giovannini L, Giannessi D, Migliori M, Bernini W, Fregoni M. et al . Antiplatelet activity of synthetic and natural resveratrol in red wine.  Int J Tissue React. 1995;  17 1-3.
• 5 Pace-Asciak C R, Hahn S, Diamandis E P, Soleas G, Goldberg D M. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease.  Clin Chim Acta. 1995;  235 207-19.
• 6 Zini R, Morin C, Bertelli A, Bertelli A A, Tillement J P. Effects of resveratrol on the rat brain respiratory chain.  Drugs Exp Clin Res. 1999;  25 87-97.
• 7 Baur J A, Sinclair D A. Therapeutic potential of resveratrol: the in vivo evidence.  Nat Rev Drug Discov. 2006;  5 493-506.
• 8 Mehta J, Mehta P. Role of blood platelets and prostaglandins in coronary artery disease.  Am J Cardiol. 1981;  48 366-73.
• 9 Wu C C, Hwang T L, Liao C H, Kuo S C, Lee F Y, Lee C Y. et al . The role of PAR4 in thrombin-induced thromboxane production in human platelets.  Thromb Haemost. 2003;  90 299-308.
• 10 Grynkiewicz G, Poenie M, Tsien R T. A new generation of Ca²⁺ indicators with greatly improved fluorescence properties.  J Biol Chem. 1985;  260 3440-50.
• 11 Wang W Y, Wu Y C, Wu C C. Prevention of platelet glycoprotein IIb/IIIa activation by a novel tyrosine kinase inhibitor 3,4-methylenedioxy-β-nitrostyrene.  Mol Pharmacol. 2006;  70 1380-9.
• 12 Schwarz U R, Walter U, Eigenthaler M. Taming platelets with cyclic nucleotides.  Biochem Pharmacol. 2001;  62 1153-61.
• 13 Hers I, Donath J, van Willigen G, Akkerman J W. Differential involvement of tyrosine and serine/threonine kinases in platelet integrin alphaIIbbeta3 exposure.  Arterioscler Thromb Vasc Biol. 1998;  18 404-14.
• 14 Elzagallaai A, Rose S D, Trifaro J M. Platelet secretion induced by phorbol esters stimulation is mediated through phosphorylation of MARCKS: a MARCKS-derived peptide blocks MARCKS phosphorylation and serotonin release without affecting pleckstrin phosphorylation.  Blood. 2000;  95 894-902.
• 15 Osusky M, Taylor S J, Shalloway D. Autophosphorylation of purified c-Src at its primary negative regulation site.  J Biol Chem. 1995;  270 25 729-32.
• 16 Shattil S J, Brass L F. Induction of the fibrinogen receptor on human platelets by intracellular mediators.  J Biol Chem. 1987;  262 992-1000.
• 17 Sargeant P, Sage S O. Calcium signalling in platelets and other nonexcitable cells.  Pharmacol Ther. 1994;  64 395-443.
• 18 de Caffoy de Courcelles D. The role of protein kinase C in the human platelet.  Blood Coagul Fibrinolysis. 1990;  1 401-13.
• 19 Slater S J, Seiz J L, Cook A C, Stagliano B A, Buzas C J. Inhibition of protein kinase C by resveratrol.  Biochim Biophys Acta. 2003;  1637 59-69.
• 20 Della Bianca V, De Togni P, Grzeskowiak M, Vicentini L M, Di Virgilio F. Cyclic AMP inhibition of phosphoinositide turnover in human neutrophils.  Biochim Biophys Acta. 1986;  886 441-7.
• 21 Jackson S P, Schoenwaelder S M, Yuan Y, Salem H H, Cooray P. Non-receptor protein tyrosine kinases and phosphatases in human platelets.  Thromb Haemost. 1996;  76 640-50.
• 22 Rendu F, Eldor A, Grelac , Bachelot C, Gazit A, Gilon C. et al . Inhibition of platelet activation by tyrosine kinase inhibitors.  Biochem Pharmacol. 1992;  44 881-8.
• 23 Law D A, Nannizzi-Alaimo L, Ministri K, Hughes P E, Forsyth J, Turner M. et al . Genetic and pharmacological analyses of Syk function in αIIbβ3 signaling in platelets.  Blood. 1999;  93 2645-52.
• 24 Kralisz U, Cierniewski C S. Activity of pp60c-src and association of pp60c-src, pp54/58lyn, pp60fyn, and pp72syk with the cytoskeleton in platelets activated by collagen.  IUBMB Life. 2000;  49 33-42.
• 25 Yu R, Hebbar V, Kim D W, Mandlekar S, Pezzuto J M, Kong A N. Resveratrol inhibits phorbol ester and UV-induced activator protein 1 activation by interfering with mitogen-activated protein kinase pathways.  Mol Pharmacol. 2001;  60 217-24.
• 26 Lin M T, Yen M L, Lin C Y, Kuo M L. Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation.  Mol Pharmacol. 2003;  64 1029-36.
• 27 Harper M T, Sage S O. PAR-1-dependent pp60src activation is dependent on protein kinase C and increased [Ca²⁺]: evidence that pp60src does not regulate PAR-1-dependent Ca²⁺ entry in human platelets.  J Thromb Haemost. 2006;  4 2695-703.
• 28 Murugappan S, Shankar H, Bhamidipati S, Dorsam R T, Jin J, Kunapuli S P. Molecular mechanism and functional implications of thrombin-mediated tyrosine phosphorylation of PKCdelta in platelets.  Blood. 2005;  106 550-7.